SlideShare una empresa de Scribd logo
1 de 10
Descargar para leer sin conexión
Definition

Community-acquired pneumonia (CAP) is defined as pneumonia in a
patient who has not been hospitalized or has not
resided in a long-term care facility (such as a
nursing home) within the past 14 days.

It is an infection of the lower respiratory tract associated with signs or
symptoms of acute infection and new CXR infiltrate.

Immunocompromised patients can get CAP, but treatment in these
individuals is different and an expanded differential diagnosis should
be considered.




                                                                             http://www.hawaii.edu/medicine/pediatrics/pemxray/v4c03.html
These are PA and lateral films of RML pneumonia (arrows).
Note the indistinct borders, air bronchograms, and silhouetting of the right
heart border.
Diagnosis for Case of the Week - April 2, 2004

                                        66 year old man s/p renal transplant with Shortness of Breathand
                                        Weight Loss




PA and Lateral films of RUL pneumonia




                                        http://www.radiology.vcu.edu/programs/residents/quiz/Pulm_COTW/2
                                        004%2004%2002%20cotw.htm
Community-acquired pneumonia                                              treatment

Key Highlights                                                            Acute
Common symptoms include :
                                                                          all patients
o    cough,
o    fever and chills,
o    fatigue,                                                                 supportive care
o    dyspnea,
o    rigors and
o    pleuritic pain                                                       outpatients


Important historical factors to narrow the differential diagnosis are :       previously healthy and drug-resistance unlikely
                                                                              macrolide or tetracycline therapy
o    recent respiratory infection,                                            comorbidities or risk factors for drug-resistant S pneumoniae
o    exposure to respiratory illnesses,
o    immunocompromise,
                                                                               infection
o    smoking,                                                                 fluoroquinolone or combination therapy
o    alcohol,
o    travel and
o    occupational risks                                                   inpatients
o    > 65 years old

                                                                              non-ICU cases
OFTEN DIAGNOSIS AND TREATMENT CAN BE BASED SOLELY ON
HISTORY AND PHYSICAL EXAM.                                                    fluoroquinolone or combination therapy
                                                                              vancomycin or linezolid
The most specific and sensitive test is CXR (PA and lateral).                 ICU cases (nonpseudomonal)
                                                                              combination therapy
Initial treatment is empirical with antibiotics.                              vancomycin or linezolid
                                                                              ICU cases (pseudomonal)
Other Factors                                                                 combination therapy

                                                                          COMPLICATIONS
o    chills then fever
o    chest pain
o    abdominal pain                                                       ARDS
o    lung percussion dullness
o    bronchial breath sounds
                                                                          Pneumonia can be complicated by ARDS, which is a condition of
o    tactile vocal fremitus
                                                                          noncardiogenic pulmonary edema and severe lung inflammation.
1st Tests To Order
                                                                          This complication is associated with a 30% to 50% mortality and is
                                                                          treated with low tidal volume plateau pressure limited mechanical
o    CXR                                                                  ventilation.
o    CBC
o    basic metabolic profile
o    oximetry or ABG                                                      EMPYEMA
o    blood culture
o    sputum culture                                                       Patients with pneumonia might have metastatic infections such as
o    sputum Gram stain
                                                                          empyema. [21]

Other Tests to Consider
                                                                          Treated with antibiotics and operative drainage.

o    rapid urinary antigen tests
                                                                          ARTHRITIS
o    thoracentesis
o    serology
o    PCR                                                                  Patients with pneumonia might have metastatic infections such as
o    M pneumoniae cold agglutinins                                        septic arthritis.
o    rapid viral diagnostic tests
o    CT chest
o    Bronchoscopy
                                                                          MENINGITIS

                                                                          Patients with pneumonia might have metastatic infections such as
                                                                          meningitis. [21]

                                                                          Treated with antibiotics that are able to cross the blood-brain barrier.
INFECTIVE ENDOCARDITIS
                                                                    Patient Instructions
Patients with pneumonia might have metastatic infections such as
endocarditis. [22]                                                  The importance of adherence to medication should be emphasized,
                                                                    even if the patient is feeling better. Patients should be instructed to
Treated with antibiotics but may require higher doses and longer    call the office if their symptoms do not improve within 72 hours.
durations than for pneumonia alone.
                                                                    Patient should be instructed to increase water intake to at least eight
PERICARDITIS                                                        8 to 12-oz glasses per day, unless otherwise contraindicated. If a
                                                                    patient is a smoker, the importance of smoking cessation during this
                                                                    illness should be stressed. Patient should be explained how smoking
Patients with pneumonia might have metastatic infections such as
                                                                    impairs natural mechanisms to eliminate pathogens and debris.
pericarditis. [21]

                                                                    To control systemic symptoms of pneumonia, aspirin or
Treated with antibiotics but may also require drainage.
                                                                    acetaminophen is recommended (aspirin should not be used in
                                                                    pediatric patients). Patient should be advised to avoid cough
                                                                    suppressants.

Patients with pneumonia might have metastatic infections such as    Patients should be advised that fatigue is common during the acute
peritonitis. [21]                                                   phase and that more rest than usual may be necessary. The patient
                                                                    can increase activity as tolerated after the acute phase.
Treated with antibiotics.




Prognosis
                                                                    Primary Prevention
Although prognosis is generally good for patients treated with
the appropriate antibiotics, roughly only 80% of patients           CDC guidelines recommend pneumococcal polysaccharide vaccine
treated with antibiotics have a resolution of clinical signs and    should be administered to: [12]
symptoms. A meta-analysis of 127 study cohorts revealed a
mortality of nearly 14%. The range is from about 5% for                     Persons aged 65 years or greater
hospitalized and ambulatory patients to over 30% for patients               Immunocompetent persons aged 2 years or greater who are
in intensive care. Factors associated with increased risk of                 at increased risk for illness and death associated with
mortality are: male sex, pleuritic chest pain, hypothermia,                  pneumococcal disease because of chronic illness
systolic hypotension, tachypnea, diabetes mellitus, neoplastic              Persons aged 2 years or greater with functional or anatomic
disease, neurologic disease, bacteremia, leukopenia and                      asplenia
multilobar radiographic pulmonary infiltrate.                               Persons aged 2 years or greater living in environments in
                                                                             which the risk for disease is high
Monitoring                                                                  Immunocompromised persons aged 2 years or greater who
                                                                             are at high risk for infection.

Monitoring parameters for CAP management should include             Protection lasts for over 6 years in most people, although the
aspects from both antimicrobial therapy and the disease state.      protective value may be lost at a faster rate in elderly people than in
Patients need to be educated on potential adverse reactions to      younger adults. Anyone at risk of serious pneumonia should be
chosen antibiotics and appropriate actions to be taken if these     revaccinated 6 years after the first dose.
occur. For example, patients should be counseled on the signs
and symptoms of severe allergic reactions and should be             Secondary Prevention
provided with emergency contact information in case of drug
side effects. Patients should also be closely monitored either in   Pneumococcal vaccine helps to prevent CAP
person or by telephone for signs and symptoms of disease
resolution or for the worsening of disease.                         Pneumonia: there is poor-quality evidence that vaccination with
                                                                    pneumococcal vaccine may be no more effective than no vaccination
Important parameters include vital signs, symptoms, and CBC         at reducing the rates of acquiring definitive pneumococcal pneumonia
and oxygen saturation. Although there is a lag time between         in immunocompetent adults.
improving clinical response and clearing of the CXR, a repeated
CXR 4 to 6 weeks after treatment may be used to ensure the
condition has not got worse.
Many viruses associated with CAP follow a seasonal pattern, including
Evidence Level C                                                          influenza virus, respiratory syncytial virus (RSV) and parainfluenza
                                                                          virus. Other viruses that can cause CAP in adults include adenovirus
Poor quality observational (cohort) studies or methodologically           and hantavirus. For infants and young children, RSV is the most
flawed randomized controlled trials (RCTs) of < 200 participants          common cause of lower respiratory tract infections, with an estimated
                                                                          25% of children hospitalized with pneumonia having RSV as the
                                                                          causative etiology.

                                                                          Pathophysiology
Emerging Therapies
                                                                          Most of the infectious agents that cause CAP are aspirated into the
Telithromycin
                                                                          lung. CAP that results from aspiration of oropharyngeal contents is the
This new ketolide antibiotic is particularly active against resistant S   only form of CAP with multiple pathogens. Among older patients,
pneumoniae strains. Telithromycin is indicated for mild-to-moderate       microaspiration of oropharyngeal secretions is common and is more
CAP. However, the most recent ATS/IDSA guidelines comment that            prevalent among patients with comorbidities and those taking
additional safety data is required before making specific                 medications that cause sedation.
recommendations for its use.
                                                                          An infection usually occurs when one component of the defense
                                                                          mechanism is not functioning properly. This results in microbial
                                                                          colonization of the upper respiratory tract. Microbes can enter and
                                                                          invade the lower respiratory tract by many methods and 6
Diagnostic Criteria                                                       mechanisms have been identified in the pathogenesis of pneumonia in
                                                                          immunocompetent adults:
Criteria for severe community-acquired pneumonia
                                                                                  Inhalation of infectious particles
Minor criteria:                                                                   Aspiration of oropharyngeal or gastric contents
                                                                                  Hematogenous deposition of bacteria in the lung
          Respiratory rate 30 breaths/minute or greater                          Invasion from infection in contiguous structures
          PaO2/FiO2 ratio 250 or less                                            Direct inoculation
          Multilobar infiltrates                                                 Reactivation.
          Confusion/disorientation
          Uremia (BUN ≥20 mg/dL)                                         Certain pre-existing conditions such as cystic fibrosis, COPD,
          Leukopenia (WBC <4000 cells/mm^3)                              corticosteroid use, immunodeficiency, stroke, drug and alcohol use,
          Thrombocytopenia (platelet count <100,000 cells/mm^3)          and pulmonary edema can hinder the ability of the host defense
          Hypothermia (core temperature <96.8ºF [36ºC])                  system to expel the possible pathogens that can predispose an
                                                                          individual to acquiring CAP.
          Hypotension, requiring aggressive fluid resuscitation

                                                                          Bacterial pathogenesis depends on the virulence and number of
Major criteria:
                                                                          organisms aspirated. For encapsulated organisms, such as S
                                                                          pneumoniae, the presence of different capsular polysaccharides,
          Invasive mechanical ventilation                                which prevent the host serum bactericidal activity (antibodies and
          Septic shock with need for vasopressors                        complement), and opsonic activity of polymorphonuclear leukocytes
                                                                          and macrophages may contribute to the pathogenesis and poor
ICU admission is recommended for patients with major criteria or 3 of     outcomes.
the minor criteria.
                                                                          Once CAP is established, host humoral and cellular responses and early
                                                                          appropriate antimicrobial therapy are critical for containing the
                                                                          infection, preventing complications and improving outcome.
                                                                          Unfortunately, the rapid emergence of antibiotic resistance and
Etiology                                                                  immune deficiency has complicated treatment decisions.

Streptococcus pneumoniae (also known as pneumococcus) is the
most common cause of CAP.

CAP can also be caused by Haemophilus influenzae, Staphylococcus
aureus, Moraxella catarrhalis, Klebsiella pneumoniae and other gram-
negative bacilli.

Atypical microorganisms and respiratory viruses can also cause CAP. A
1996 prospective study identified the prevalence of various pathogens
in 346 consecutive patients with CAP. Mycoplasma pneumoniae,
Chlamydia pneumoniae and Legionella species accounted for 29%, 18%
and 16% of cases, respectively.
14 CAP, COMMUNITY ASQUIRED PNEUMONIA
14 CAP, COMMUNITY ASQUIRED PNEUMONIA
14 CAP, COMMUNITY ASQUIRED PNEUMONIA
14 CAP, COMMUNITY ASQUIRED PNEUMONIA

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Dev
DevDev
Dev
 
Pneumonia overview and ncp
Pneumonia  overview and ncpPneumonia  overview and ncp
Pneumonia overview and ncp
 
Pneumonia ( Classification,Types and causes,Diagnosis,Treatment Recovery and ...
Pneumonia ( Classification,Types and causes,Diagnosis,Treatment Recovery and ...Pneumonia ( Classification,Types and causes,Diagnosis,Treatment Recovery and ...
Pneumonia ( Classification,Types and causes,Diagnosis,Treatment Recovery and ...
 
Pneumonia (Pathophysiology and management) by Sunil Kumar Daha
Pneumonia (Pathophysiology and management) by Sunil Kumar DahaPneumonia (Pathophysiology and management) by Sunil Kumar Daha
Pneumonia (Pathophysiology and management) by Sunil Kumar Daha
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
PneumoniaCheck by ARC Medical, The link between diagnosis and treatment of Pn...
PneumoniaCheck by ARC Medical, The link between diagnosis and treatment of Pn...PneumoniaCheck by ARC Medical, The link between diagnosis and treatment of Pn...
PneumoniaCheck by ARC Medical, The link between diagnosis and treatment of Pn...
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Pneumonia
Pneumonia Pneumonia
Pneumonia
 
med
medmed
med
 
Pneumonia
Pneumonia Pneumonia
Pneumonia
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
pneumonia
pneumoniapneumonia
pneumonia
 
Pathology of Pneumonia
Pathology of PneumoniaPathology of Pneumonia
Pathology of Pneumonia
 
Pneumonia
Pneumonia Pneumonia
Pneumonia
 
Pneumonia by Dr. Sookun Rajeev Kumar
Pneumonia by Dr. Sookun Rajeev KumarPneumonia by Dr. Sookun Rajeev Kumar
Pneumonia by Dr. Sookun Rajeev Kumar
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Bacterial pneumonia pharmacology
Bacterial pneumonia pharmacologyBacterial pneumonia pharmacology
Bacterial pneumonia pharmacology
 
Pneumonia drharsha md
Pneumonia drharsha md Pneumonia drharsha md
Pneumonia drharsha md
 

Destacado

Respiratory assessment
Respiratory assessmentRespiratory assessment
Respiratory assessmentkatieleigh920
 
stroke first aids
stroke first aidsstroke first aids
stroke first aidskdiwavvou
 
26 Dysphagia
26 Dysphagia26 Dysphagia
26 Dysphagiakdiwavvou
 
15 rheymatoid arthritis
15 rheymatoid arthritis15 rheymatoid arthritis
15 rheymatoid arthritiskdiwavvou
 
θυρεοτοξικωση
θυρεοτοξικωσηθυρεοτοξικωση
θυρεοτοξικωσηkdiwavvou
 
7 Anticoagulant Antiplatelet Fibrinolytic
7 Anticoagulant Antiplatelet Fibrinolytic7 Anticoagulant Antiplatelet Fibrinolytic
7 Anticoagulant Antiplatelet Fibrinolytickdiwavvou
 
28 Coma Exam
28 Coma Exam28 Coma Exam
28 Coma Examkdiwavvou
 
3 Kidney And Fluids
3 Kidney And Fluids3 Kidney And Fluids
3 Kidney And Fluidskdiwavvou
 
42 Lipids Diagram
42 Lipids Diagram42 Lipids Diagram
42 Lipids Diagramkdiwavvou
 
33 Diverticuliti S
33 Diverticuliti S33 Diverticuliti S
33 Diverticuliti Skdiwavvou
 
46 Electrolytes
46 Electrolytes46 Electrolytes
46 Electrolyteskdiwavvou
 
52 Respir Atory Patt Er Ns
52 Respir Atory   Patt Er Ns52 Respir Atory   Patt Er Ns
52 Respir Atory Patt Er Nskdiwavvou
 
0 6 Viral Hepatitis
0 6 Viral Hepatitis0 6 Viral Hepatitis
0 6 Viral Hepatitiskdiwavvou
 
44 Ecg Final
44 Ecg Final44 Ecg Final
44 Ecg Finalkdiwavvou
 
23 Urinalysis
23 Urinalysis23 Urinalysis
23 Urinalysiskdiwavvou
 
24 Pyelonephritis
24 Pyelonephritis24 Pyelonephritis
24 Pyelonephritiskdiwavvou
 
11 External Stuff About Dermatomes Pics
11 External Stuff      About Dermatomes  Pics11 External Stuff      About Dermatomes  Pics
11 External Stuff About Dermatomes Picskdiwavvou
 
Case report fatal pneumothorax after ERCP
Case report fatal pneumothorax after ERCPCase report fatal pneumothorax after ERCP
Case report fatal pneumothorax after ERCPMuhammad Asim Rana
 
100289400 case-study-on-pneumonia-real
100289400 case-study-on-pneumonia-real100289400 case-study-on-pneumonia-real
100289400 case-study-on-pneumonia-realhomeworkping7
 

Destacado (20)

Respiratory assessment
Respiratory assessmentRespiratory assessment
Respiratory assessment
 
stroke first aids
stroke first aidsstroke first aids
stroke first aids
 
26 Dysphagia
26 Dysphagia26 Dysphagia
26 Dysphagia
 
15 rheymatoid arthritis
15 rheymatoid arthritis15 rheymatoid arthritis
15 rheymatoid arthritis
 
θυρεοτοξικωση
θυρεοτοξικωσηθυρεοτοξικωση
θυρεοτοξικωση
 
7 Anticoagulant Antiplatelet Fibrinolytic
7 Anticoagulant Antiplatelet Fibrinolytic7 Anticoagulant Antiplatelet Fibrinolytic
7 Anticoagulant Antiplatelet Fibrinolytic
 
28 Coma Exam
28 Coma Exam28 Coma Exam
28 Coma Exam
 
3 Kidney And Fluids
3 Kidney And Fluids3 Kidney And Fluids
3 Kidney And Fluids
 
42 Lipids Diagram
42 Lipids Diagram42 Lipids Diagram
42 Lipids Diagram
 
33 Diverticuliti S
33 Diverticuliti S33 Diverticuliti S
33 Diverticuliti S
 
46 Electrolytes
46 Electrolytes46 Electrolytes
46 Electrolytes
 
4 0 Bun
4 0 Bun4 0 Bun
4 0 Bun
 
52 Respir Atory Patt Er Ns
52 Respir Atory   Patt Er Ns52 Respir Atory   Patt Er Ns
52 Respir Atory Patt Er Ns
 
0 6 Viral Hepatitis
0 6 Viral Hepatitis0 6 Viral Hepatitis
0 6 Viral Hepatitis
 
44 Ecg Final
44 Ecg Final44 Ecg Final
44 Ecg Final
 
23 Urinalysis
23 Urinalysis23 Urinalysis
23 Urinalysis
 
24 Pyelonephritis
24 Pyelonephritis24 Pyelonephritis
24 Pyelonephritis
 
11 External Stuff About Dermatomes Pics
11 External Stuff      About Dermatomes  Pics11 External Stuff      About Dermatomes  Pics
11 External Stuff About Dermatomes Pics
 
Case report fatal pneumothorax after ERCP
Case report fatal pneumothorax after ERCPCase report fatal pneumothorax after ERCP
Case report fatal pneumothorax after ERCP
 
100289400 case-study-on-pneumonia-real
100289400 case-study-on-pneumonia-real100289400 case-study-on-pneumonia-real
100289400 case-study-on-pneumonia-real
 

Similar a 14 CAP, COMMUNITY ASQUIRED PNEUMONIA

SEVER Viral pneumonia last
SEVER Viral pneumonia lastSEVER Viral pneumonia last
SEVER Viral pneumonia lastDr.Tarek Sabry
 
BRONCHO PNEUMONIA PRESESNTATION.pptx
BRONCHO PNEUMONIA PRESESNTATION.pptxBRONCHO PNEUMONIA PRESESNTATION.pptx
BRONCHO PNEUMONIA PRESESNTATION.pptxeguyujohn1
 
Update management of CAP
Update management of CAPUpdate management of CAP
Update management of CAPSaher Farghly
 
Acs0402 Cough And Hemoptysis
Acs0402 Cough And HemoptysisAcs0402 Cough And Hemoptysis
Acs0402 Cough And Hemoptysismedbookonline
 
Bronchiectasis and other lung suppurative diseases
Bronchiectasis and other lung suppurative diseasesBronchiectasis and other lung suppurative diseases
Bronchiectasis and other lung suppurative diseasesHisham Alrabty
 
Overview of community-acquired pneumonia in adults.pdf
Overview of community-acquired pneumonia in adults.pdfOverview of community-acquired pneumonia in adults.pdf
Overview of community-acquired pneumonia in adults.pdfDr Emad efat
 
NON-RESOLVING PNEUMONIA.pptx
NON-RESOLVING PNEUMONIA.pptxNON-RESOLVING PNEUMONIA.pptx
NON-RESOLVING PNEUMONIA.pptxGouriMohan7
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Gamal Agmy
 
1 PNEUMONIA-.. [YR 4] APRIL 2022_102703.pptx
1 PNEUMONIA-.. [YR 4] APRIL 2022_102703.pptx1 PNEUMONIA-.. [YR 4] APRIL 2022_102703.pptx
1 PNEUMONIA-.. [YR 4] APRIL 2022_102703.pptxAngetileKasanga
 
Non resolving pneumonia
Non resolving pneumoniaNon resolving pneumonia
Non resolving pneumoniaSayantan Saha
 
Infiltrative eosinophilias of lung
Infiltrative eosinophilias of lungInfiltrative eosinophilias of lung
Infiltrative eosinophilias of lungDinoosh De Livera
 

Similar a 14 CAP, COMMUNITY ASQUIRED PNEUMONIA (20)

Pneumonia
PneumoniaPneumonia
Pneumonia
 
SEVER Viral pneumonia last
SEVER Viral pneumonia lastSEVER Viral pneumonia last
SEVER Viral pneumonia last
 
BRONCHO PNEUMONIA PRESESNTATION.pptx
BRONCHO PNEUMONIA PRESESNTATION.pptxBRONCHO PNEUMONIA PRESESNTATION.pptx
BRONCHO PNEUMONIA PRESESNTATION.pptx
 
Update management of CAP
Update management of CAPUpdate management of CAP
Update management of CAP
 
Acs0402 Cough And Hemoptysis
Acs0402 Cough And HemoptysisAcs0402 Cough And Hemoptysis
Acs0402 Cough And Hemoptysis
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Bronchiectasis and other lung suppurative diseases
Bronchiectasis and other lung suppurative diseasesBronchiectasis and other lung suppurative diseases
Bronchiectasis and other lung suppurative diseases
 
Overview of community-acquired pneumonia in adults.pdf
Overview of community-acquired pneumonia in adults.pdfOverview of community-acquired pneumonia in adults.pdf
Overview of community-acquired pneumonia in adults.pdf
 
NON-RESOLVING PNEUMONIA.pptx
NON-RESOLVING PNEUMONIA.pptxNON-RESOLVING PNEUMONIA.pptx
NON-RESOLVING PNEUMONIA.pptx
 
pneumonia-1.pdf
pneumonia-1.pdfpneumonia-1.pdf
pneumonia-1.pdf
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Pcp
PcpPcp
Pcp
 
Non resolving pneumonia
Non resolving pneumoniaNon resolving pneumonia
Non resolving pneumonia
 
1 PNEUMONIA-.. [YR 4] APRIL 2022_102703.pptx
1 PNEUMONIA-.. [YR 4] APRIL 2022_102703.pptx1 PNEUMONIA-.. [YR 4] APRIL 2022_102703.pptx
1 PNEUMONIA-.. [YR 4] APRIL 2022_102703.pptx
 
PNEUMONIA.pdf
PNEUMONIA.pdfPNEUMONIA.pdf
PNEUMONIA.pdf
 
Non resolving pneumonia
Non resolving pneumoniaNon resolving pneumonia
Non resolving pneumonia
 
16 Pneumonie.pdf
16 Pneumonie.pdf16 Pneumonie.pdf
16 Pneumonie.pdf
 
Infiltrative eosinophilias of lung
Infiltrative eosinophilias of lungInfiltrative eosinophilias of lung
Infiltrative eosinophilias of lung
 
Mediastinitis
MediastinitisMediastinitis
Mediastinitis
 

Más de kdiwavvou

56 Establishing A Bedside Diagnosis Of Hypovolemia
56    Establishing A Bedside Diagnosis Of Hypovolemia56    Establishing A Bedside Diagnosis Of Hypovolemia
56 Establishing A Bedside Diagnosis Of Hypovolemiakdiwavvou
 
55 Aldosterone Inhibitors Diuretic S
55    Aldosterone Inhibitors  Diuretic S55    Aldosterone Inhibitors  Diuretic S
55 Aldosterone Inhibitors Diuretic Skdiwavvou
 
50 Myeloproliferative Disease
50 Myeloproliferative Disease50 Myeloproliferative Disease
50 Myeloproliferative Diseasekdiwavvou
 
46 Electrolyte Replacement
46 Electrolyte Replacement46 Electrolyte Replacement
46 Electrolyte Replacementkdiwavvou
 
35 G I Functional Dearangements
35  G I Functional Dearangements35  G I Functional Dearangements
35 G I Functional Dearangementskdiwavvou
 
42 Lipids Diagram
42 Lipids Diagram42 Lipids Diagram
42 Lipids Diagramkdiwavvou
 
42 2 Dyslipidemia
42 2 Dyslipidemia42 2 Dyslipidemia
42 2 Dyslipidemiakdiwavvou
 
44 Ecg Final
44 Ecg Final44 Ecg Final
44 Ecg Finalkdiwavvou
 
38 Hypertension
38 Hypertension38 Hypertension
38 Hypertensionkdiwavvou
 
36 A N T I H Y P E R T E N S I V E D R U G S
36  A N T I H Y P E R T E N S I V E  D R U G S36  A N T I H Y P E R T E N S I V E  D R U G S
36 A N T I H Y P E R T E N S I V E D R U G Skdiwavvou
 
36 Antipyretensive Drugs
36 Antipyretensive Drugs36 Antipyretensive Drugs
36 Antipyretensive Drugskdiwavvou
 
36 Antihypertensive Drugs
36 Antihypertensive Drugs36 Antihypertensive Drugs
36 Antihypertensive Drugskdiwavvou
 
Gi Functional Dearangements
Gi Functional DearangementsGi Functional Dearangements
Gi Functional Dearangementskdiwavvou
 
32 Osteoporosis Drugs
32 Osteoporosis Drugs32 Osteoporosis Drugs
32 Osteoporosis Drugskdiwavvou
 

Más de kdiwavvou (20)

56 Establishing A Bedside Diagnosis Of Hypovolemia
56    Establishing A Bedside Diagnosis Of Hypovolemia56    Establishing A Bedside Diagnosis Of Hypovolemia
56 Establishing A Bedside Diagnosis Of Hypovolemia
 
55 Aldosterone Inhibitors Diuretic S
55    Aldosterone Inhibitors  Diuretic S55    Aldosterone Inhibitors  Diuretic S
55 Aldosterone Inhibitors Diuretic S
 
50 Myeloproliferative Disease
50 Myeloproliferative Disease50 Myeloproliferative Disease
50 Myeloproliferative Disease
 
46 Electrolyte Replacement
46 Electrolyte Replacement46 Electrolyte Replacement
46 Electrolyte Replacement
 
35 G I Functional Dearangements
35  G I Functional Dearangements35  G I Functional Dearangements
35 G I Functional Dearangements
 
42 Lipids Diagram
42 Lipids Diagram42 Lipids Diagram
42 Lipids Diagram
 
42 2 Dyslipidemia
42 2 Dyslipidemia42 2 Dyslipidemia
42 2 Dyslipidemia
 
44 Ecg Final
44 Ecg Final44 Ecg Final
44 Ecg Final
 
44 E C G
44 E C G44 E C G
44 E C G
 
38 Hypertension
38 Hypertension38 Hypertension
38 Hypertension
 
37 Vitamins
37 Vitamins37 Vitamins
37 Vitamins
 
36 A N T I H Y P E R T E N S I V E D R U G S
36  A N T I H Y P E R T E N S I V E  D R U G S36  A N T I H Y P E R T E N S I V E  D R U G S
36 A N T I H Y P E R T E N S I V E D R U G S
 
36 Antipyretensive Drugs
36 Antipyretensive Drugs36 Antipyretensive Drugs
36 Antipyretensive Drugs
 
32 I R S
32   I R S32   I R S
32 I R S
 
36 Antihypertensive Drugs
36 Antihypertensive Drugs36 Antihypertensive Drugs
36 Antihypertensive Drugs
 
Gi Functional Dearangements
Gi Functional DearangementsGi Functional Dearangements
Gi Functional Dearangements
 
34 Ileus
34 Ileus34 Ileus
34 Ileus
 
32 Irs
32  Irs32  Irs
32 Irs
 
32 Irs
32 Irs32 Irs
32 Irs
 
32 Osteoporosis Drugs
32 Osteoporosis Drugs32 Osteoporosis Drugs
32 Osteoporosis Drugs
 

Último

call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...saminamagar
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingArunagarwal328757
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 

Último (20)

call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, Pricing
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 

14 CAP, COMMUNITY ASQUIRED PNEUMONIA

  • 1. Definition Community-acquired pneumonia (CAP) is defined as pneumonia in a patient who has not been hospitalized or has not resided in a long-term care facility (such as a nursing home) within the past 14 days. It is an infection of the lower respiratory tract associated with signs or symptoms of acute infection and new CXR infiltrate. Immunocompromised patients can get CAP, but treatment in these individuals is different and an expanded differential diagnosis should be considered. http://www.hawaii.edu/medicine/pediatrics/pemxray/v4c03.html
  • 2. These are PA and lateral films of RML pneumonia (arrows). Note the indistinct borders, air bronchograms, and silhouetting of the right heart border.
  • 3. Diagnosis for Case of the Week - April 2, 2004 66 year old man s/p renal transplant with Shortness of Breathand Weight Loss PA and Lateral films of RUL pneumonia http://www.radiology.vcu.edu/programs/residents/quiz/Pulm_COTW/2 004%2004%2002%20cotw.htm
  • 4. Community-acquired pneumonia treatment Key Highlights Acute Common symptoms include : all patients o cough, o fever and chills, o fatigue,  supportive care o dyspnea, o rigors and o pleuritic pain outpatients Important historical factors to narrow the differential diagnosis are :  previously healthy and drug-resistance unlikely  macrolide or tetracycline therapy o recent respiratory infection,  comorbidities or risk factors for drug-resistant S pneumoniae o exposure to respiratory illnesses, o immunocompromise, infection o smoking,  fluoroquinolone or combination therapy o alcohol, o travel and o occupational risks inpatients o > 65 years old  non-ICU cases OFTEN DIAGNOSIS AND TREATMENT CAN BE BASED SOLELY ON HISTORY AND PHYSICAL EXAM.  fluoroquinolone or combination therapy  vancomycin or linezolid The most specific and sensitive test is CXR (PA and lateral).  ICU cases (nonpseudomonal)  combination therapy Initial treatment is empirical with antibiotics.  vancomycin or linezolid  ICU cases (pseudomonal) Other Factors  combination therapy COMPLICATIONS o chills then fever o chest pain o abdominal pain ARDS o lung percussion dullness o bronchial breath sounds Pneumonia can be complicated by ARDS, which is a condition of o tactile vocal fremitus noncardiogenic pulmonary edema and severe lung inflammation. 1st Tests To Order This complication is associated with a 30% to 50% mortality and is treated with low tidal volume plateau pressure limited mechanical o CXR ventilation. o CBC o basic metabolic profile o oximetry or ABG EMPYEMA o blood culture o sputum culture Patients with pneumonia might have metastatic infections such as o sputum Gram stain empyema. [21] Other Tests to Consider Treated with antibiotics and operative drainage. o rapid urinary antigen tests ARTHRITIS o thoracentesis o serology o PCR Patients with pneumonia might have metastatic infections such as o M pneumoniae cold agglutinins septic arthritis. o rapid viral diagnostic tests o CT chest o Bronchoscopy MENINGITIS Patients with pneumonia might have metastatic infections such as meningitis. [21] Treated with antibiotics that are able to cross the blood-brain barrier.
  • 5. INFECTIVE ENDOCARDITIS Patient Instructions Patients with pneumonia might have metastatic infections such as endocarditis. [22] The importance of adherence to medication should be emphasized, even if the patient is feeling better. Patients should be instructed to Treated with antibiotics but may require higher doses and longer call the office if their symptoms do not improve within 72 hours. durations than for pneumonia alone. Patient should be instructed to increase water intake to at least eight PERICARDITIS 8 to 12-oz glasses per day, unless otherwise contraindicated. If a patient is a smoker, the importance of smoking cessation during this illness should be stressed. Patient should be explained how smoking Patients with pneumonia might have metastatic infections such as impairs natural mechanisms to eliminate pathogens and debris. pericarditis. [21] To control systemic symptoms of pneumonia, aspirin or Treated with antibiotics but may also require drainage. acetaminophen is recommended (aspirin should not be used in pediatric patients). Patient should be advised to avoid cough suppressants. Patients with pneumonia might have metastatic infections such as Patients should be advised that fatigue is common during the acute peritonitis. [21] phase and that more rest than usual may be necessary. The patient can increase activity as tolerated after the acute phase. Treated with antibiotics. Prognosis Primary Prevention Although prognosis is generally good for patients treated with the appropriate antibiotics, roughly only 80% of patients CDC guidelines recommend pneumococcal polysaccharide vaccine treated with antibiotics have a resolution of clinical signs and should be administered to: [12] symptoms. A meta-analysis of 127 study cohorts revealed a mortality of nearly 14%. The range is from about 5% for  Persons aged 65 years or greater hospitalized and ambulatory patients to over 30% for patients  Immunocompetent persons aged 2 years or greater who are in intensive care. Factors associated with increased risk of at increased risk for illness and death associated with mortality are: male sex, pleuritic chest pain, hypothermia, pneumococcal disease because of chronic illness systolic hypotension, tachypnea, diabetes mellitus, neoplastic  Persons aged 2 years or greater with functional or anatomic disease, neurologic disease, bacteremia, leukopenia and asplenia multilobar radiographic pulmonary infiltrate.  Persons aged 2 years or greater living in environments in which the risk for disease is high Monitoring  Immunocompromised persons aged 2 years or greater who are at high risk for infection. Monitoring parameters for CAP management should include Protection lasts for over 6 years in most people, although the aspects from both antimicrobial therapy and the disease state. protective value may be lost at a faster rate in elderly people than in Patients need to be educated on potential adverse reactions to younger adults. Anyone at risk of serious pneumonia should be chosen antibiotics and appropriate actions to be taken if these revaccinated 6 years after the first dose. occur. For example, patients should be counseled on the signs and symptoms of severe allergic reactions and should be Secondary Prevention provided with emergency contact information in case of drug side effects. Patients should also be closely monitored either in Pneumococcal vaccine helps to prevent CAP person or by telephone for signs and symptoms of disease resolution or for the worsening of disease. Pneumonia: there is poor-quality evidence that vaccination with pneumococcal vaccine may be no more effective than no vaccination Important parameters include vital signs, symptoms, and CBC at reducing the rates of acquiring definitive pneumococcal pneumonia and oxygen saturation. Although there is a lag time between in immunocompetent adults. improving clinical response and clearing of the CXR, a repeated CXR 4 to 6 weeks after treatment may be used to ensure the condition has not got worse.
  • 6. Many viruses associated with CAP follow a seasonal pattern, including Evidence Level C influenza virus, respiratory syncytial virus (RSV) and parainfluenza virus. Other viruses that can cause CAP in adults include adenovirus Poor quality observational (cohort) studies or methodologically and hantavirus. For infants and young children, RSV is the most flawed randomized controlled trials (RCTs) of < 200 participants common cause of lower respiratory tract infections, with an estimated 25% of children hospitalized with pneumonia having RSV as the causative etiology. Pathophysiology Emerging Therapies Most of the infectious agents that cause CAP are aspirated into the Telithromycin lung. CAP that results from aspiration of oropharyngeal contents is the This new ketolide antibiotic is particularly active against resistant S only form of CAP with multiple pathogens. Among older patients, pneumoniae strains. Telithromycin is indicated for mild-to-moderate microaspiration of oropharyngeal secretions is common and is more CAP. However, the most recent ATS/IDSA guidelines comment that prevalent among patients with comorbidities and those taking additional safety data is required before making specific medications that cause sedation. recommendations for its use. An infection usually occurs when one component of the defense mechanism is not functioning properly. This results in microbial colonization of the upper respiratory tract. Microbes can enter and invade the lower respiratory tract by many methods and 6 Diagnostic Criteria mechanisms have been identified in the pathogenesis of pneumonia in immunocompetent adults: Criteria for severe community-acquired pneumonia  Inhalation of infectious particles Minor criteria:  Aspiration of oropharyngeal or gastric contents  Hematogenous deposition of bacteria in the lung  Respiratory rate 30 breaths/minute or greater  Invasion from infection in contiguous structures  PaO2/FiO2 ratio 250 or less  Direct inoculation  Multilobar infiltrates  Reactivation.  Confusion/disorientation  Uremia (BUN ≥20 mg/dL) Certain pre-existing conditions such as cystic fibrosis, COPD,  Leukopenia (WBC <4000 cells/mm^3) corticosteroid use, immunodeficiency, stroke, drug and alcohol use,  Thrombocytopenia (platelet count <100,000 cells/mm^3) and pulmonary edema can hinder the ability of the host defense  Hypothermia (core temperature <96.8ºF [36ºC]) system to expel the possible pathogens that can predispose an individual to acquiring CAP.  Hypotension, requiring aggressive fluid resuscitation Bacterial pathogenesis depends on the virulence and number of Major criteria: organisms aspirated. For encapsulated organisms, such as S pneumoniae, the presence of different capsular polysaccharides,  Invasive mechanical ventilation which prevent the host serum bactericidal activity (antibodies and  Septic shock with need for vasopressors complement), and opsonic activity of polymorphonuclear leukocytes and macrophages may contribute to the pathogenesis and poor ICU admission is recommended for patients with major criteria or 3 of outcomes. the minor criteria. Once CAP is established, host humoral and cellular responses and early appropriate antimicrobial therapy are critical for containing the infection, preventing complications and improving outcome. Unfortunately, the rapid emergence of antibiotic resistance and Etiology immune deficiency has complicated treatment decisions. Streptococcus pneumoniae (also known as pneumococcus) is the most common cause of CAP. CAP can also be caused by Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, Klebsiella pneumoniae and other gram- negative bacilli. Atypical microorganisms and respiratory viruses can also cause CAP. A 1996 prospective study identified the prevalence of various pathogens in 346 consecutive patients with CAP. Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella species accounted for 29%, 18% and 16% of cases, respectively.